Industry
Biotechnology
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
May 31, 2024 | 12:03 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 10:41 am
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 11:03 am
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 11:02 am
Portfolio Pulse from Benzinga Newsdesk
April 30, 2024 | 10:37 am
Portfolio Pulse from Benzinga Newsdesk
April 05, 2024 | 8:36 pm
Portfolio Pulse from Benzinga Newsdesk
April 01, 2024 | 10:23 am
Portfolio Pulse from Benzinga Newsdesk
March 28, 2024 | 12:56 pm
Portfolio Pulse from Benzinga Newsdesk
March 28, 2024 | 12:50 pm
Portfolio Pulse from Benzinga Newsdesk
March 28, 2024 | 11:01 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.